showed the improved efficacy of the combination treatment of FAP CAR‐T cells and EphA2 CAR‐T cells, leading to the clearance of FAP+ tumor‐associated fibroblasts and enhancing the treatment outcome of CAR‐T cells targeting the tumor‐associated antigen EphA2 locally and systemically.[91] Matrix components such as collagens and HA are also being investigated as possible targets to overcome physical barriers and further facilitate cancer immunotherapy using cell‐based delivery systems. The gene discussed is EPHA2; the disease is neoplasm.